Redhill Biopharma RDHL 深 沪
交易中 10-06 11:18:36 美东时间
0.4998
+0.007
+1.38%
华盛通- 最 高1.60
- 今 开0.495
- 成交量 1.77万股
- 最 低 0.4647
- 昨 收 0.493
- 总市值 2.66万
- 52周最高 2.14
- 市盈率 静 --
- 换手率 0.03%
- 52周最低 0.4647
- 委 比 96.95%
- 总股本 5.33万
- 历史最高 22220.00
- 量 比 0.92
- 振 幅 230.28%
- 历史最低 0.4647
- 每 手 1
- 风险率 0.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Redhill Biopharma H1 2026 EPS $0.00 And Revenue $0.00
Redhill Biopharma (NASDAQ:RDHL) reported H1 2026 EPS $0.00 And Revenue $0.00.
10-01 04:36
Market-Moving News for January 5th
ALT: 24% | Altimmune shares are trading higher after the FDA granted Breakthrough Therapy Designation for Pemvidutide in MASH. RDHL: 52% | RedHill Expands RHB-102 Clinical Development Addressing GLP-1
01-05 20:44
RedHill Expands RHB-102 Clinical Development Addressing GLP-1 Therapy-Related GI Side Effects And Broader GI Indications
RHB-1021 is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroenteritis and gastritis,
01-05 20:15
RedHill Biopharma Says Opaganib Gets FDA Orphan Drug Designation for Neuroblastoma
07:38 AM EDT, 08/26/2024 (MT Newswires) -- RedHill Biopharma (RDHL) said Monday that the US Food and Drug Administration granted orphan drug designation for opaganib as a treatment for neuroblastoma, a type of childhood cancer. Besides accelerated review, the designation provides opaganib a seven-ye...
2024-08-26 19:38
Redhill Biopharma Launches Talicia for H. pylori Infection in UAE
08:04 AM EDT, 08/21/2024 (MT Newswires) -- Redhill Biopharma (RDHL) said Wednesday it has launched Talicia by prescription in the United Arab Emirates to treat H. pylori infections in adults. The company said the launch makes RedHill eligible for additional milestone payments, minimum sales payments...
2024-08-21 20:04
Redhill Biopharma's Shares Jump Premarket on Positive Study Results for Opaganib
07:44 AM EDT, 08/19/2024 (MT Newswires) -- Redhill Biopharma (RDHL) said Monday that it achieved positive results from multiple in vivo studies conducted by RedHill's partner, Apogee Biotechnology Corporation, supporting the potential clinical use of opaganib for the prevention and therapy of Type 2...
2024-08-19 19:44
Redhill Biopharma to Change American Depositary Share Ratio
08:27 AM EDT, 08/16/2024 (MT Newswires) -- Redhill Biopharma (RDHL) said Friday that it will change the ratio of its American depositary shares to its non-traded ordinary shares to a new ratio of one ADS representing 10,000 ordinary shares from the current ratio of one ADS representing 400 ordinary ...
2024-08-16 20:27
